Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 402-411 |
| Number of pages | 10 |
| Journal | Journal of Hepatology |
| Volume | 68 |
| Issue number | 3 |
| Early online date | 25 Oct 2017 |
| DOIs | |
| Publication status | Published - Mar 2018 |
Fingerprint
Keywords
- HCV treatment
- HCV transmission
- injecting drug users
Cite this
}
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. / Fraser, Hannah; Martin, Natasha K.; Brummer-Korvenkontio, Henrikki ; Carrieri, Patrizia; Dalgard, Olav; Dillon, John; Goldberg, David; Hutchinson, Sharon; Jauffret-Roustide, Marie; Kåberg, Martin; Matser, Amy A.; Maticic, Mojca; Midgard, Havard; Mravcik, Viktor; Øvrehus, Anne; Prins, Maria; Reimer, Jens; Robaeys, Geert; Schulte, Bernd; van Santen, Daniela K.; Zimmermann, Ruth; Vickerman, Peter; Hickman, Matthew.
In: Journal of Hepatology, Vol. 68, No. 3, 03.2018, p. 402-411.Research output: Contribution to journal › Article
TY - JOUR
T1 - Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
AU - Fraser, Hannah
AU - Martin, Natasha K.
AU - Brummer-Korvenkontio, Henrikki
AU - Carrieri, Patrizia
AU - Dalgard, Olav
AU - Dillon, John
AU - Goldberg, David
AU - Hutchinson, Sharon
AU - Jauffret-Roustide, Marie
AU - Kåberg, Martin
AU - Matser, Amy A.
AU - Maticic, Mojca
AU - Midgard, Havard
AU - Mravcik, Viktor
AU - Øvrehus, Anne
AU - Prins, Maria
AU - Reimer, Jens
AU - Robaeys, Geert
AU - Schulte, Bernd
AU - van Santen, Daniela K.
AU - Zimmermann, Ruth
AU - Vickerman, Peter
AU - Hickman, Matthew
N1 - Acceptance email in SAN AAM: 12m embargo Copyright held by client org. ET 8-1-18
PY - 2018/3
Y1 - 2018/3
N2 - Background: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical to eliminating HCV in Europe. We estimate impact of current and scaled-up HCV treatment with and without scaling-up opioid substitution therapy (OST) and needle and syringe programmes (NSP) across Europe over the next 10 years. Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST and NSP coverage from 11 European settings. We parameterized a HCV transmission model to setting-specific data that projects chronic HCV prevalence and incidence among PWID. Results: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. Current treatment rates using new direct acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia and Amsterdam. Doubling HCV-treatment rates will reduce prevalence in other sites (12-24%, Belgium/Denmark/Hamburg/Norway/Scotland) but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100pyrs or less in 10 years. Moderate to substantial increases in current treatment rates are required to achieve the same impact elsewhere, from 1.4-3 times (Czech Republic/France), 5-17 times 5 (France/Scotland/Hamburg/Norway/Denmark/Belgium/Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%. Conclusions: Scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.
AB - Background: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical to eliminating HCV in Europe. We estimate impact of current and scaled-up HCV treatment with and without scaling-up opioid substitution therapy (OST) and needle and syringe programmes (NSP) across Europe over the next 10 years. Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST and NSP coverage from 11 European settings. We parameterized a HCV transmission model to setting-specific data that projects chronic HCV prevalence and incidence among PWID. Results: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. Current treatment rates using new direct acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia and Amsterdam. Doubling HCV-treatment rates will reduce prevalence in other sites (12-24%, Belgium/Denmark/Hamburg/Norway/Scotland) but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100pyrs or less in 10 years. Moderate to substantial increases in current treatment rates are required to achieve the same impact elsewhere, from 1.4-3 times (Czech Republic/France), 5-17 times 5 (France/Scotland/Hamburg/Norway/Denmark/Belgium/Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%. Conclusions: Scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.
KW - HCV treatment
KW - HCV transmission
KW - injecting drug users
U2 - 10.1016/j.jhep.2017.10.010
DO - 10.1016/j.jhep.2017.10.010
M3 - Article
VL - 68
SP - 402
EP - 411
IS - 3
ER -